Event Description
Topic
Use of Solanezumab Aβ Amyloid Humanized Monoclonal Antibody in Asymptomatic Alzheimer’s Disease Patients
Hosted By
Drexel Neurosciences Institute
Speaker
Yasir Al-Khalili, MD, Drexel Neurosciences Institute
Learning Objectives
- Discuss updates in Alzheimer's disease treatments
- Discuss advances in treatment therapy and overview of previous studies
- Discuss the pathophysiology and epidemiology of Alzheimer's dementia in the population
Target Audience
DUCOM faculty, all physicians, fellows, residents, medical students, PAs, CRNPs, RNs, all medical specialties
Continuing Medical Education Credits
Drexel University College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA
Credit Designation Statement: The Drexel University College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AOA: This program is eligible for 1 credit in Category 2A of the American Osteopathic Association.
Disclosure
Speakers at continuing medical education activities are required to disclose to the audience, any relevant commercial interest (which is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients). Any conflicts of interest must be resolved prior to the presentation and announced to the audience.
Yasir Al-Khalili, MD, has no commercial relationships to disclose. |
